Roivant Sciences Ltd.’s plans for broadening the reach of recently approved TYK2/JAK1 inhibitor Lisraya (brepocitinib) got a boost on positive phase III data demonstrating solid efficacy in non-infectious uveitis, an indication in dire need of new treatment options.
Bioworld
Original source
Proposed collaboration covers scientific exchange, specialist training and real-world evidence, alongside assessment of clinical trial opportunities and a potential regional presence for NeOnc in Abu Dhabi
BOSTON--(BUSINESS WIRE)--AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, today announced it has entered into a Research Collaboration and License Agreement with Astellas Innovation Management LLC, an affiliate of Astellas Pharma Inc. (TSE: 4503), to discover and develop novel miniprotein-based therapeutics. Under the terms of the agreement, AI Proteins is eligible to receive over $400 million in upfront and milest
26 line-km of seismic data across the Cobequid-Chedabucto Fault Zone now in processing; results to be integrated with soil-gas data to define drill targetsHalifax, Nova Scotia--(Newsfile Corp. - Oc...
TEHRAN - Iraqi Ambassador to Iran Yasser Abdulzahra Al-Hajjaj has stressed that scientific cooperation between the two countries should extend beyond student recruitment to include joint research projects, exchanges of professors and researchers, and stronger technological ties.
Headlines and briefs on this site are for information only. Always verify details on the original source or live status page.
Read Disclaimer